Anti-NFKB1 Monoclonal Antibody for WB, IHC-P, IP, ELISA, CHIP - P19838

Core Product Specifications and Parameters

Biological Background: NF-kB Function and Localization

• NF-κB is a pleiotropic transcription factor present in nearly all cell types, acting as the endpoint of signaling cascades triggered by diverse stimuli and regulating processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis, and apoptosis.
• NF-κB functions as homo- or heterodimeric complexes formed by Rel-like domain-containing proteins including RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL, and NFKB2/p52; the p65-p50 heterodimer is the most abundant form.
• NFKB1 encodes a 105 kDa precursor (p105) that undergoes cotranslational proteasome-mediated processing to generate the active 50 kDa DNA-binding subunit (p50). Related references: PMID:1423592
• The p50 subunit associates with RELA/p65 to form the NF-κB p65-p50 heterodimer, which binds the consensus κB site 5′-GGRNNYYCC-3′ in enhancer regions of immune response and acute phase reaction genes. Related references: PMID:1740106, PMID:7830764
• While p65-p50 and RelB-p50 heterodimers act as transcriptional activators, the p50-p50 homodimer functions as a repressor but can switch to an activator upon association with BCL3.
• NFKB1/p105 also serves as a cytoplasmic retention molecule for associated NF-κB proteins, keeping them inactive in the cytoplasm; its degradation by the ubiquitin-proteasome system releases active MAP3K8 to propagate MAPK signaling.
• Subcellular localization is dynamic: NF-κB complexes reside primarily in the cytoplasm in an inactive state bound to IκB inhibitors and translocate to the nucleus upon activation.
• Post-translational modifications including phosphorylation, acetylation, hydroxylation, and ubiquitination regulate NFKB1 activity, stability, and interactions.

Experimental Guidance and Technical Tips

• For Western blot, nuclear and cytoplasmic fractionation may help distinguish p105 (105 kDa) and p50 (50 kDa) bands; validate with appropriate loading controls.
• In IHC-P, consider optimizing antigen retrieval and validating staining patterns with known NF-κB-positive (e.g., immune tissues) and -negative controls.
• For CHIP, verify that the antibody can enrich κB-site-containing promoter regions; pilot experiments with positive (e.g., TNFA) and negative genomic loci are recommended.
• Given the immunogen is a synthetic peptide, cross-reactivity with other NF-κB family members should be assessed by siRNA knockdown or competition with the immunizing peptide.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. This anti-NFKB1 monoclonal antibody supports research in inflammation, immunity, and oncology, and is available alongside validated antibody pairs, optimized bulk reagents, and rare target sourcing. For custom formulations or scale-up, contact our team to streamline your IVD development pipeline.